PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: PRICE T ROWE ASSOCIATES INC discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 6 November 2026, by SEC EDGAR SCHEDULE 13G
30Impact 30 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Price T. Rowe Associates Inc. disclosed a stake exceeding 5% in Pacific Biosciences of California Inc. via a Schedule 13G filing with the SEC (accession 0000080255-26-000673). The exact share count and percentage were not specified in the headline disclosure. The move signals heightened institutional interest in the genetic-sequencing company. Investors will watch for further detail on the position size and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Price T Rowe Associates Inc, Pacific Biosciences of California, Inc.